Company intelligence / Profile preview
Alphyn Biologics
Annapolis, Maryland, USAalphynbiologics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company’s lead asset, Zabalafin Hydrogel (AB‑101a), has completed two Phase 2a clinical trials in atopic dermatitis—both cohorts met all primary and secondary endpoints. Results showed significant improvements in itch reduction, quality of life, inflammation control, clearance of infected AD skin, and control of staph-associated flares. The product demonstrated minimal side effects and excellent tolerability. A global Phase 2b trial began dosing patients in April 2025.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Multi-target therapeutics (botanical drug with multiple bioactive compounds)topical hydrogel formulationsmall molecules (inferred from botanical origin and multi-bioactive approach)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Alphyn Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alphyn Biologics.